The progress of ALS research and clinical practice is hampered by lack of effective biomarkers to monitor disease onset and progression. In response to this urgent need, we will integrate single-cell system biology approaches, histopathological and clinical data from precious human nerve biopsies collected from living ALS patients during the diagnostic workup and findings from innovative preclinical mouse models to unmask cell-specific molecular alterations that arise in the PNS tissue during the course of ALS pathology. This information will be used to select protein biomarkers of dysfunctional states associated with pre-manifest or early symptomatic stages of the disease, which will be further screened and validated in patient biofluids. Altogether, this project will lead to the discovery of novel, reliable and specific ALS biomarkers while providing insights into ALS mechanisms by leveraging an original "PNS perspective" on disease pathogenesis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for als patients:
* Age equal or over 18 years old
* ALS patients, diagnosed accordingly to the revised El Escorial Criteria
* Disease duration \<24 months from symptom onset.
Exclusion Criteria for als patients:
* FVC \<60%;
* nutritional or respiratory failure;
* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
Inclusion criteria for ALS pre-symptomatic patients
* Age equal or over 18 years old
* Patients with genetic defined susceptibility to ALS and one or more strict relative affected from ALS Exclusion criteria for ALS pre-symptomatic patients
* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
Inclusion criteria for controls
* Age equal or over 18 years old
* Subjects without a diagnosis of neurodegenerative disease or neuromuscular disorder.
Exclusion criteria for controls
• significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
Inclusion criteria for non ALS neurodegenerative patients
* Age equal or over 18 years old
* For AD: Diagnosis according to 2018 NIA-AA Framework for Alzheimer's Disease
* For FTD: Diagnosis according to 2011 International Behavioural Variant FTD Criteria Consortium
* For PD: Diagnosis according to 2015 Movement Disorder Society criteria
* For DLB: Diagnosis according to 2017 Fourth Consensus Report of the DLB Consortium Exclusion criteria for non ALS neurodegenerative patients
* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
Inclusion criteria for neuromuscular disease patients
* Age equal or over 18 years old
* Presence of axonal or demyelinating neuropathy Exclusion criteria for neuromuscular patients
* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.
Primary outcome measure(s)
Diagnostic ALS biomarkers — 20 months Throughout the study, we will validate, starting from transcriptomics data, novel diagnostic biomarker for an early diagnosis of ALS
Trial sites (4)
Facility
City
Region
Status
Azienda Ospedaliero Universitaria di Cagliari
Monserrato
California
Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan
Italy
Recruiting
IRCCS Ospedale San Raffaele SRL
Milan
Italy
Recruiting
Azienda Ospedaliera Universitaria Federico II
Naples
Italy
Recruiting
More Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
